Sequencing Agents In Metastatic Prostate Cancer Ppt 4. e3805 chaarted: chemohormonal therapy vs. androgen ablation for metastatic prostate cancer sweeney c et al. n engl j med 2015; 373:737 46. • n=790 men accrued 07 28 06 11 21 12 • planned interim analysis at 53% information met 10 13 • 01 16 14 median followup 29 months • 136 (110 high volume) deaths adt alone vs. 101 (82 high volume) deaths adt d • 83.6% vs. 83.2% of deaths from. Treatment intensification strategies are reshaping the treatment landscape of metastatic castration resistant prostate cancer. genomic, molecular, and clinical indicators should be used to identify the optimal therapeutic pathway for each patient.
Treatment Of Metastatic Prostate Cancer How Urologists Should Sequence Management of metastatic prostate cancer has undergone a revolution over the past decade with the introduction of several novel agents and repurposing of others. several clinical trials reported improved outcomes with the intensification of androgen deprivation therapy by the addition of docetaxel chemotherapy or novel hormonal agents (abiraterone, enzalutamide, or apalutamide) in the. This document discusses treatment options for metastatic prostate cancer. it begins by outlining first line hormonal therapies like androgen deprivation therapy using lhrh agonists or antagonists. it then discusses secondary hormonal manipulations for castration resistant prostate cancer, including antiandrogens, cyp17a inhibitors, and estrogens. Introduction. in the past decade, emerging intensification strategies have revolutionized the systemic treatment paradigm of prostate cancer. combining an androgen receptor pathway inhibitor (arpi) with the traditional androgen deprivation therapy (adt) is now the standard of care for the treatment of metastatic hormone naïve (mhnpc) and nonmetastatic castration resistant (nmcrpc) prostate. Genomic sequencing studies have identified a high frequency of alterations involving cancer related genes in metastatic prostate tumors 35,36,37, including those commonly seen in localized disease.
Comments are closed.